Sisram Medical Management
Management criteria checks 2/4
Sisram Medical's CEO is Lior Dayan, appointed in Jun 2017, has a tenure of 7.5 years. total yearly compensation is $1.53M, comprised of 56.6% salary and 43.4% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth HK$2.70M. The average tenure of the management team and the board of directors is 1.9 years and 7.3 years respectively.
Key information
Lior Dayan
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 56.6% |
| CEO tenure | 7.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.9yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Investors Could Be Concerned With Sisram Medical's (HKG:1696) Returns On Capital
Dec 11
What Sisram Medical Ltd's (HKG:1696) 40% Share Price Gain Is Not Telling You
Oct 07Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?
Aug 23Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Just Yet
Jul 24Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)
Jun 17Returns On Capital At Sisram Medical (HKG:1696) Have Stalled
Apr 21Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?
Mar 28Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)
Mar 05Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)
Jan 23Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?
Dec 29Is Sisram Medical (HKG:1696) Using Too Much Debt?
Nov 09Returns On Capital At Sisram Medical (HKG:1696) Have Stalled
Oct 19At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?
Sep 18Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year
Aug 14Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?
Jun 16Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue
May 30Is Sisram Medical (HKG:1696) Using Too Much Debt?
Apr 19Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?
Mar 01Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital
Jan 12Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet
Dec 21Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?
Dec 01Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital
Oct 14Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching
Sep 28These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely
Aug 25Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?
Aug 01These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely
May 19Is Sisram Medical Ltd (HKG:1696) Trading At A 29% Discount?
May 03If You Like EPS Growth Then Check Out Sisram Medical (HKG:1696) Before It's Too Late
Apr 11Sisram Medical (HKG:1696) Is Experiencing Growth In Returns On Capital
Mar 17Is Now An Opportune Moment To Examine Sisram Medical Ltd (HKG:1696)?
Nov 22Calculating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)
Aug 22Be Wary Of Sisram Medical (HKG:1696) And Its Returns On Capital
Jul 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$28m |
| Dec 31 2023 | US$2m | US$863k | US$31m |
| Sep 30 2023 | n/a | n/a | US$35m |
| Jun 30 2023 | n/a | n/a | US$38m |
| Mar 31 2023 | n/a | n/a | US$39m |
| Dec 31 2022 | US$3m | US$1m | US$40m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$35m |
| Mar 31 2022 | n/a | n/a | US$33m |
| Dec 31 2021 | US$2m | US$767k | US$31m |
| Sep 30 2021 | n/a | n/a | US$28m |
| Jun 30 2021 | n/a | n/a | US$24m |
| Mar 31 2021 | n/a | n/a | US$19m |
| Dec 31 2020 | US$769k | US$596k | US$13m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | US$13m |
| Mar 31 2020 | n/a | n/a | US$17m |
| Dec 31 2019 | US$759k | US$606k | US$21m |
| Sep 30 2019 | n/a | n/a | US$22m |
| Jun 30 2019 | n/a | n/a | US$24m |
| Mar 31 2019 | n/a | n/a | US$23m |
| Dec 31 2018 | US$884k | US$560k | US$22m |
Compensation vs Market: Lior's total compensation ($USD1.53M) is above average for companies of similar size in the Hong Kong market ($USD352.22K).
Compensation vs Earnings: Lior's compensation has been consistent with company performance over the past year.
CEO
Lior Dayan (54 yo)
7.5yrs
Tenure
US$1,526,000
Compensation
Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and its President since 2023 and is responsible for its overall and day-to-day manageme...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.7yrs | US$27.00k | 0.042% HK$ 711.8k | |
| President | 7.5yrs | US$1.53m | 0.16% HK$ 2.7m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 6.7yrs | no data | no data | |
| VP of Finance | 1.9yrs | no data | no data | |
| Chief Information Officer | 1.1yrs | no data | no data | |
| Chief Marketing Officer | 1.9yrs | no data | no data | |
| Chief People Officer | 1.9yrs | no data | no data | |
| President of ROW | 1.9yrs | no data | no data | |
| EVP of R&D | 1.9yrs | no data | no data | |
| President NA | 1.9yrs | no data | no data | |
| Company Secretary | 2.9yrs | no data | no data |
1.9yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 1696's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.7yrs | US$27.00k | 0.042% HK$ 711.8k | |
| President | 7.5yrs | US$1.53m | 0.16% HK$ 2.7m | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | no data | |
| Non-Executive Director | 8.2yrs | no data | no data | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | no data | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | no data | |
| Independent Non-Executive Director | 7.3yrs | US$32.00k | no data | |
| Non-Executive Director | 4.3yrs | no data | no data |
7.3yrs
Average Tenure
51.5yo
Average Age
Experienced Board: 1696's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 08:51 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sisram Medical Ltd is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Gao | China International Capital Corporation Limited |
| Yifan Du | Citic Securities Co., Ltd. |
| Eugene Huang | Jefferies LLC |